@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix chebi: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix do: . @prefix occursIn: . @prefix obo: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:1705; a Protein: . sub:_2 occursIn: do:162, obo:CL_0000451, obo:UBERON_0002106, species:9606; rdf:object sub:_1; rdf:predicate belv:increases; rdf:subject chebi:36498; a rdf:Statement . sub:assertion rdfs:label "a(CHEBI:galactosylceramide) -> p(HGNC:CD86)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_4; pav:version "20131211" . sub:_3 prov:value "a-galactosylceramide promotes the expression of CD80/CD86 and MHC molecules on splenic DC, but CD40ligation is needed to link innate and cognate immune responses. Moreover, tumor cells loaded with a-galactosylceramide elicited potent antitumor immune protections involving CD1d-mediated cross-presentation of tumor antigens by splenic DC (Shimizu et al., 2007)."; prov:wasQuotedFrom pubmed:18836473 . sub:_4 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:18836473; prov:wasDerivedFrom beldoc:, sub:_3 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:26.453+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }